Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, announced its state-of-the-art facility will open in the first quarter of 2025 in West Valley City, Utah. The 170,000-square-foot production facility will create and supply rare isotopes to the healthcare and pharmaceutical industry to support patient care and enable the next generation of radiotherapeutics.
Nusano CEO Chris Lowe made the opening date announcement at Jefferies’ Inaugural Radiopharma Summit in New York City on April 3 where the company participated as a featured presenter and panelist.
“Based upon Nusano’s proprietary ion source, our production facility is the first significant rare isotope manufacturing advancement in decades,” says Lowe. “Small and efficient, the Nusano platform can generate up to 12 different radioisotopes simultaneously. This efficiency and flexibility will allow Nusano to overcome supply and production limitations which have plagued the industry.”
Radioisotopes serve as active pharmaceutical ingredients (APIs) in radiopharmaceuticals used to diagnose and treat cancer, Alzheimer’s, heart disease and other diseases. Increasingly, advanced medicines and treatment methods are using radioisotopes to target and eliminate cancer cells with precision.
Mr. Lowe continued, “Healthcare has used radioisotopes for decades, but supply has not kept up with demand. Nusano is working to supply the fight against cancer so patients do not have to wait for life-changing care and treatments. With our production facility’s opening date announced, we are now engaging in discussions with therapeutic and diagnostic developers about how Nusano can help solve supply bottlenecks, accelerate product development, and improve patient care.”